Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
about
Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR PathwayGeno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsCorrelation between vitamin D levels and apoptosis in geriatric patients infected with hepatitis C virus genotype 4.Management of hepatitis C genotype 4 in the directly acting antivirals era.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.Hepatitis C virus whole genome sequencing: Current methods/issues and future challenges.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infectionResistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Evaluation of the cobas® GT hepatitis C virus genotyping assay in G1-6 viruses including low viral loads and LiPA failures.Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents
P2860
Q26700090-A36FA681-963A-41EC-BFA4-FC1DCB79DB24Q28552269-E92ADEAD-AE5E-462D-912C-454E4127FB07Q36888680-EC2EE286-5820-4FB7-A36B-FBB93F42EE50Q37312151-FF080CDA-8494-47D9-AABC-37A898B55498Q38779980-89CE261B-E031-44CF-9A8C-2BC1EDC74976Q38805659-63CA7B25-7196-4700-9A34-0C84F0B9065AQ38893128-036201D9-178F-4D20-97D8-231F24F1434CQ40518926-20342CD6-7F43-4B0B-97D8-3ED117885D5EQ40634052-1BC1A736-55FC-4AF6-A518-B65B69639F4DQ40829360-8FC1953E-0239-412E-B327-7E05D68BAEFCQ41923068-85714D84-C73E-4D04-AC0E-E624253CFAC9Q45325504-87B59FDE-2304-4988-AC6A-69E4485C1D0EQ52346277-3649D820-23DB-4DBC-89D4-A15CED96568DQ59125732-054230D1-0470-4FA4-967C-226FF72E8B4A
P2860
Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Hepatitis C virus genotype 4 r ...... r plus paritaprevir/ritonavir.
@ast
Hepatitis C virus genotype 4 r ...... r plus paritaprevir/ritonavir.
@en
type
label
Hepatitis C virus genotype 4 r ...... r plus paritaprevir/ritonavir.
@ast
Hepatitis C virus genotype 4 r ...... r plus paritaprevir/ritonavir.
@en
prefLabel
Hepatitis C virus genotype 4 r ...... r plus paritaprevir/ritonavir.
@ast
Hepatitis C virus genotype 4 r ...... r plus paritaprevir/ritonavir.
@en
P2093
P2860
P50
P356
P1476
Hepatitis C virus genotype 4 r ...... r plus paritaprevir/ritonavir.
@en
P2093
Christine Collins
Coleen Hall
Gretja Schnell
Jill Beyer
Liangjun Lu
Preethi Krishnan
Rakesh Tripathi
Regis A Vilchez
Tami Pilot-Matias
Tatyana Dekhtyar
P2860
P304
P356
10.1128/AAC.01229-15
P407
P577
2015-08-17T00:00:00Z